Evolus, Inc. (EOLS) stock
EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.52−0.48 (-6.86%)
Close on Nov 20, 2026Market cap $430.65MP/E –Yield –
Evolus gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Evolus's gross profit for the twelve months ending Jun 30, 2026 was $211.21M, up 13.1% year over year. For fiscal 2025 it was $197.11M, up 8.1% from the year before. The highest annual figure on record is $197.11M in fiscal 2025.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $197.11M | +8.1% |
| FY2024 | Dec 31, 2024 | $182.30M | +32.5% |
| FY2023 | Dec 31, 2023 | $137.57M | +53.2% |
| FY2022 | Dec 31, 2022 | $89.77M | +59.9% |
| FY2021 | Dec 31, 2021 | $56.14M | +46.8% |
| FY2020 | Dec 31, 2020 | $38.24M | +42.1% |
| FY2019 | Dec 31, 2019 | $26.91M | – |
| FY2018 | Dec 31, 2018 | $0 | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $57.18M | +26.2% |
| Q1 FY2026 | Mar 31, 2026 | $48.90M | +4.8% |
| Q4 FY2025 | Dec 31, 2025 | $59.29M | +12.6% |
| Q3 FY2025 | Sep 30, 2025 | $45.84M | +8.9% |
| Q2 FY2025 | Jun 30, 2025 | $45.32M | -3.7% |
| Q1 FY2025 | Mar 31, 2025 | $46.66M | +15.2% |
| Q4 FY2024 | Dec 31, 2024 | $52.63M | +35.7% |
| Q3 FY2024 | Sep 30, 2024 | $42.10M | +21.7% |
| Q2 FY2024 | Jun 30, 2024 | $47.07M | +35.9% |
| Q1 FY2024 | Mar 31, 2024 | $40.50M | +37.0% |
| Q4 FY2023 | Dec 31, 2023 | $38.77M | +41.9% |
| Q3 FY2023 | Sep 30, 2023 | $34.59M | +69.5% |
| Q2 FY2023 | Jun 30, 2023 | $34.63M | +62.3% |
| Q1 FY2023 | Mar 31, 2023 | $29.58M | +42.9% |
| Q4 FY2022 | Dec 31, 2022 | $27.32M | +45.1% |
| Q3 FY2022 | Sep 30, 2022 | $20.41M | +34.4% |
| Q2 FY2022 | Jun 30, 2022 | $21.34M | +44.3% |
| Q1 FY2022 | Mar 31, 2022 | $20.70M | +182.3% |
| Q4 FY2021 | Dec 31, 2021 | $18.82M | +41.5% |
| Q3 FY2021 | Sep 30, 2021 | $15.19M | +18.6% |
| Q2 FY2021 | Jun 30, 2021 | $14.80M | +152.6% |
| Q1 FY2021 | Mar 31, 2021 | $7.33M | +16.8% |
| Q4 FY2020 | Dec 31, 2020 | $13.30M | -15.9% |
| Q3 FY2020 | Sep 30, 2020 | $12.81M | +35.5% |
| Q2 FY2020 | Jun 30, 2020 | $5.86M | +254.8% |
| Q1 FY2020 | Mar 31, 2020 | $6.28M | – |
| Q4 FY2019 | Dec 31, 2019 | $15.81M | – |
| Q3 FY2019 | Sep 30, 2019 | $9.45M | – |
| Q2 FY2019 | Jun 30, 2019 | $1.65M | – |
| Q1 FY2019 | Mar 31, 2019 | $0 | – |
| Q4 FY2018 | Dec 31, 2018 | $0 | – |
| Q3 FY2018 | Sep 30, 2018 | $0 | – |
| Q2 FY2018 | Jun 30, 2018 | $0 | – |
See a number that looks wrong?